530 related articles for article (PubMed ID: 22510564)
1. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
Issaenko OA; Amerik AY
Cell Cycle; 2012 May; 11(9):1804-17. PubMed ID: 22510564
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S
Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.
Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M
Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
Kapuria V; Peterson LF; Fang D; Bornmann WG; Talpaz M; Donato NJ
Cancer Res; 2010 Nov; 70(22):9265-76. PubMed ID: 21045142
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
7. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
8. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
[TBL] [Abstract][Full Text] [Related]
9. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.
Anchoori RK; Khan SR; Sueblinvong T; Felthauser A; Iizuka Y; Gavioli R; Destro F; Isaksson Vogel R; Peng S; Roden RB; Bazzaro M
PLoS One; 2011; 6(8):e23888. PubMed ID: 21909374
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Berges C; Haberstock H; Fuchs D; Miltz M; Sadeghi M; Opelz G; Daniel V; Naujokat C
Immunology; 2008 Jun; 124(2):234-46. PubMed ID: 18217957
[TBL] [Abstract][Full Text] [Related]
11. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS
Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
16. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
[TBL] [Abstract][Full Text] [Related]
19. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S
Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031
[TBL] [Abstract][Full Text] [Related]
20. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
